PHIL Invests in State-of-the-Art Cash Dispense Capabilities, Expanding Direct-to-Patient Fulfillment for Pharma

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--PHIL Inc. today announced a significant expansion of its cash dispense capabilities, a major strategic investment that positions the company to continue serving the rapidly growing direct-to-patient (DTP) market, helping pharmaceutical companies get medications in the hands of patients at scale.

After seeing 20x growth in cash dispenses in 2025, PHIL introduced these enhanced capabilities to support an all-time-high prescription volume while building capacity for significant growth in the future.

"Direct-to-patient programs are evolving faster than ever, and pharma needs the right operational infrastructure to successfully keep pace with patient expectations," said Sahil Naik, Chief Growth Officer at PHIL. "We’re seeing extremely positive reception from patients from this initiative, and we’re excited to continue our momentum helping pharma manufacturers offer a best-in-class prescription fulfillment experience through PHILRx.”

PHIL’s expanded network seamlessly integrates technology-driven workflows and state-of-the-art dispensing capabilities to maximize accuracy, speed, and throughput, reducing fulfillment times and operational costs while maintaining the highest standards of quality, control, and experience.

"Our new cash dispense capabilities are gamechanging," said Robert Schumaker, VP of Pharmacy Network & Wholesale Operations at PHIL. "With a nationwide network licensed in all 50 states that serves over a million patients each year, the investment takes this strong foundation to the next level, giving our pharma partners the ability to meet the explosive growth of direct-to-patient access."

About PHIL Inc.: PHIL is a healthcare technology company that helps pharmaceutical manufacturers streamline medication access for patients. PHIL's digital hub and direct-to-patient platform is purpose-built to improve access, affordability, and adherence at scale. For more information, visit phil.us.